Literature DB >> 23278834

Effects of three different medications on metabolic parameters and testicular volume in patients with hypogonadotropic hypogonadism: 3-year experience.

Aydogan Aydogdu1, Erol Bolu, Alper Sonmez, Ilker Tasci, Cem Haymana, Ramazan Acar, Coskun Meric, Abdullah Taslipinar, Taner Ozgurtas, Omer Azal.   

Abstract

INTRODUCTION: The aim of this study was to demonstrate the influences of three different treatment strategies on biochemical parameters and testicular volume (TV) in patients with idiopathic hypogonadotropic hypogonadism (IHH). SUBJECTS DESIGN AND METHODS: Seventy-seven never-treated patients with IHH and age and body mass index (BMI)-matched 42 healthy controls were analysed in a retrospective design. Twenty-eight patients were treated with testosterone esters (TE), 25 patients were treated with human chorionic gonadotropin (hCG) and 24 patients were treated with testosterone gel (TG). Biochemical parameters, tanner stages (TS) and TV were evaluated before and after 6 months of treatment.
RESULTS: Pretreatment TV, TS and biochemical test results were similar among the three treatment subgroup. In the TE-treated group, BMI, haemoglobin, haematocrit, creatinine, triglyceride, total testosterone (TT), TS and TV increased, but HDL-cholesterol (C) and urea level decreased significantly. In the hCG-treated group, triglyceride level decreased, and luteinizing hormone level, TS and TV increased significantly. BMI, TT, TS and TV increased, and leucocyte count, total-C, HDL-C levels decreased significantly in the TG-treated patients. No treatment type resulted in any changes in insulin resistance markers.
CONCLUSION: hCG treatment resulted in favourable effects particularly on TV and lipid parameters. When TV improvement is considered less important, TG treatment may be a better option for older patients with IHH because of its easy use, neutral effects on triglyceride, haemoglobin and haematocrit, and its beneficial effects on total cholesterol level.
© 2012 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23278834     DOI: 10.1111/cen.12135

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Osteocalcin Levels in Male Idiopathic Hypogonadotropic Hypogonadism: Relationship With the Testosterone Secretion and Metabolic Profiles.

Authors:  Yu-Ying Yang; Si-Chang Zheng; Wen-Cui Wang; Zu-Wei Yang; Chang Shan; Yu-Wen Zhang; Yan Qi; Yu-Hong Chen; Wei-Qiong Gu; Wei-Qing Wang; Hong-Yan Zhao; Jian-Min Liu; Shou-Yue Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-11       Impact factor: 5.555

2.  Testosterone versus hCG in Hypogonadotropic Hypogonadism - Comparing Clinical Effects and Evaluating Current Practice.

Authors:  Swashti Agarwal; Duong D Tu; Paul F Austin; Michael E Scheurer; Lefkothea P Karaviti
Journal:  Glob Pediatr Health       Date:  2020-09-23

3.  Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism.

Authors:  Chen-Xi Li; Song-Tao Tang; Qiu Zhang
Journal:  Int J Endocrinol       Date:  2015-08-31       Impact factor: 3.257

4.  Testosterone undecanoate supplementation together with human chorionic gonadotropin does not impair spermatogenesis in males with isolated hypogonadotropic hypogonadism: a retrospective study.

Authors:  Yin-Wei Chen; Yong-Hua Niu; Hao Xu; Dao-Qi Wang; Hong-Yang Jiang; Gaurab Pokhrel; Tao Wang; Shao-Gang Wang; Ji-Hong Liu
Journal:  Asian J Androl       Date:  2019 Jul-Aug       Impact factor: 3.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.